Mark Jankelow
Psychiatric/Mental Health · Colorado Springs, CONPI 1487958070
Payments from drug & device makers
Across 869 payments — averaging $330.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$123K
- Vanda Pharmaceuticals Inc.$52K
- Otsuka America Pharmaceutical, Inc.$38K
- Axsome Therapeutics, Inc.$26K
- Teva Pharmaceuticals USA, Inc.$20K
- Alkermes, Inc.$17K
- plus $10K from 19 others
What the payments were for
- Consulting fees$7,4443%
- Speaking & faculty fees$219,74476%
- Travel & lodging$41,98915%
- Food & beverage$18,1186%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 323 | $123,283 |
| Vanda Pharmaceuticals Inc. | 83 | $52,280 |
| Otsuka America Pharmaceutical, Inc. | 110 | $37,884 |
| Axsome Therapeutics, Inc. | 63 | $26,340 |
| Teva Pharmaceuticals USA, Inc. | 99 | $20,490 |
| Alkermes, Inc. | 68 | $17,264 |
| E.r. Squibb & Sons, L.L.C. | 20 | $5,219 |
| Neurocrine Biosciences, Inc. | 12 | $1,697 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $772 |
| Sunovion Pharmaceuticals Inc. | 12 | $584 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $443 |
| Lundbeck LLC | 14 | $301 |
| Idorsia Pharmaceuticals US Inc | 4 | $137 |
| Tris Pharma Inc | 3 | $136 |
| Indivior Inc. | 7 | $128 |
| Eisai Inc. | 5 | $85 |
| USWM, LLC | 3 | $63 |
| Braeburn Inc. | 3 | $58 |
| Merck | 3 | $54 |
| Avanir Pharmaceuticals, Inc. | 2 | $48 |
| Tempus AI, Inc | 2 | $41 |
| Johnson & Johnson | 2 | $36 |
| Almatica Pharma LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,392 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 128 | $187,767 |
| RexultiBrexpiprazole | 86 | $141,835 |
| IngrezzaValbenazine Tosylate | 15 | $133,752 |
| Austedo XrDeutetrabenazine | 18 | $105,210 |
| TrintellixVortioxetine Hydrobromide | 126 | $80,051 |
| AustedoDeutetrabenazine | 11 | $55,523 |
| LatudaLurasidone Hcl | 14 | $32,350 |
| BelsomraSuvorexant | 72 | $32,337 |
| DayvigoLemborexant | 37 | $12,725 |
| Aripiprazole | 94 | $5,864 |
| Divalproex Sodium ErDivalproex Sodium | 47 | $4,939 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $4,526 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $4,101 |
| Lurasidone Hcl | 16 | $3,965 |
| Vilazodone Hcl | 38 | $3,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $123,283 | $187,767128 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $20,490 | $160,73229 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37,884 | $141,83586 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,697 | $133,75215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $772 | $84,577140 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $584 | $32,35014 claims |
| MerckBelsomra | $54 | $32,33772 claims |
| Eisai Inc.Dayvigo | $85 | $12,72537 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $83347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 873 psychiatric/mental health providers in Colorado.
Other psychiatric/mental health in Colorado Springs
- Cristi BundukamaraColorado Springs$230K
- Jennie StormesColorado Springs$12K
- Kimberly SmithColorado Springs$9K
- Lewis SwarthoutColorado Springs$7K
- Ann ChartrandColorado Springs$7K
- Kristin MagnusonColorado Springs$7K
- Shannon GravesColorado Springs$6K
- Alison BakerColorado Springs$6K
- Patricia BursnallColorado Springs$5K
- Kayla PrevidiColorado Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.